Literature DB >> 20089902

Transient overexpression of alpha-Ca2+/calmodulin-dependent protein kinase II in the nucleus accumbens shell enhances behavioral responding to amphetamine.

Jessica A Loweth1, Bryan F Singer, Lorinda K Baker, Georgia Wilke, Hidetoshi Inamine, Nancy Bubula, John K Alexander, William A Carlezon, Rachael L Neve, Paul Vezina.   

Abstract

Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) is known to contribute to the expression of psychostimulant sensitization by regulating dopamine (DA) overflow from DA neuron terminals in the nucleus accumbens (NAcc). The present experiments explored the contribution of CaMKII in NAcc neurons postsynaptic to these terminals where it is known to participate in a number of signaling pathways that regulate responding to psychostimulant drugs. Exposure to amphetamine transiently increased alphaCaMKII levels in the shell but not the core of the NAcc. Thus, HSV (herpes simplex viral) vectors were used to transiently overexpress alphaCaMKII in NAcc neurons in drug-naive rats, and behavioral responding to amphetamine was assessed. Transiently overexpressing alphaCaMKII in the NAcc shell led to long-lasting enhancement of amphetamine-induced locomotion and self-administration manifested when alphaCaMKII levels were elevated and persisting long after they had returned to baseline. Enhanced locomotion was not observed after infection in the NAcc core or sites adjacent to the NAcc. Transient elevation of NAcc shell alphaCaMKII levels also enhanced locomotor responding to NAcc AMPA and increased phosphorylation levels of GluR1 (Ser831), a CaMKII site, both soon and long after infection. Similar increases in pGluR1 (Ser831) were observed both soon and long after exposure to amphetamine. These results indicate that the transient increase in alphaCaMKII observed in neurons of the NAcc shell after viral-mediated gene transfer and likely exposure to amphetamine leads to neuroadaptations in AMPA receptor signaling in this site that may contribute to the long-lasting maintenance of behavioral and incentive sensitization by psychostimulant drugs like amphetamine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20089902      PMCID: PMC2825054          DOI: 10.1523/JNEUROSCI.4383-09.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  76 in total

1.  Enhanced dopamine release and phosphorylation of synapsin I and neuromodulin in striatal synaptosomes after repeated amphetamine.

Authors:  S I Iwata; G H Hewlett; S T Ferrell; L Kantor; M E Gnegy
Journal:  J Pharmacol Exp Ther       Date:  1997-12       Impact factor: 4.030

Review 2.  The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants.

Authors:  M E Wolf
Journal:  Prog Neurobiol       Date:  1998-04       Impact factor: 11.685

3.  Introduction of the glutamate receptor subunit 1 into motor neurons in vitro and in vivo using a recombinant herpes simplex virus.

Authors:  R L Neve; J R Howe; S Hong; R G Kalb
Journal:  Neuroscience       Date:  1997-07       Impact factor: 3.590

4.  Calcium-mediated second messengers modulate the expression of behavioral sensitization to cocaine.

Authors:  R C Pierce; E A Quick; D C Reeder; Z R Morgan; P W Kalivas
Journal:  J Pharmacol Exp Ther       Date:  1998-09       Impact factor: 4.030

5.  Effects of the AMPA receptor antagonist NBQX on the development and expression of behavioral sensitization to cocaine and amphetamine.

Authors:  Y Li; A J Vartanian; F J White; C J Xue; M E Wolf
Journal:  Psychopharmacology (Berl)       Date:  1997-12       Impact factor: 4.530

6.  Stabilization of dendritic arbor structure in vivo by CaMKII.

Authors:  G Y Wu; H T Cline
Journal:  Science       Date:  1998-01-09       Impact factor: 47.728

7.  Behavioral sensitization to amphetamine is not accompanied by changes in glutamate receptor surface expression in the rat nucleus accumbens.

Authors:  Christopher L Nelson; Michael Milovanovic; Joseph B Wetter; Kerstin A Ford; Marina E Wolf
Journal:  J Neurochem       Date:  2009-01-22       Impact factor: 5.372

8.  Inhibition of CaMKII in the nucleus accumbens shell decreases enhanced amphetamine intake in sensitized rats.

Authors:  Jessica A Loweth; Lorinda K Baker; Tarra Guptaa; Anitra M Guillory; Paul Vezina
Journal:  Neurosci Lett       Date:  2008-08-07       Impact factor: 3.046

9.  Activity-dependent modulation of limbic dopamine D3 receptors by CaMKII.

Authors:  Xian-Yu Liu; Li-Min Mao; Guo-Chi Zhang; Christopher J Papasian; Eugene E Fibuch; Hong-Xiang Lan; Hui-Fang Zhou; Ming Xu; John Q Wang
Journal:  Neuron       Date:  2009-02-12       Impact factor: 17.173

10.  Sensitization to morphine induced by viral-mediated gene transfer.

Authors:  W A Carlezon; V A Boundy; C N Haile; S B Lane; R G Kalb; R L Neve; E J Nestler
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

View more
  34 in total

1.  Alterations in AMPA receptor subunits and TARPs in the rat nucleus accumbens related to the formation of Ca²⁺-permeable AMPA receptors during the incubation of cocaine craving.

Authors:  Carrie R Ferrario; Jessica A Loweth; Mike Milovanovic; Kerstin A Ford; Gregorio L Galiñanes; Li-Jun Heng; Kuei Y Tseng; Marina E Wolf
Journal:  Neuropharmacology       Date:  2011-01-27       Impact factor: 5.250

2.  Sex differences and effects of cocaine on excitatory synapses in the nucleus accumbens.

Authors:  Anne Marie Wissman; Andrew F McCollum; Guang-Zhe Huang; Amisra A Nikrodhanond; Catherine S Woolley
Journal:  Neuropharmacology       Date:  2011-04-13       Impact factor: 5.250

Review 3.  AMPA receptor plasticity in the nucleus accumbens after repeated exposure to cocaine.

Authors:  Marina E Wolf; Carrie R Ferrario
Journal:  Neurosci Biobehav Rev       Date:  2010-01-28       Impact factor: 8.989

4.  Transient viral-mediated overexpression of alpha-calcium/calmodulin-dependent protein kinase II in the nucleus accumbens shell leads to long-lasting functional upregulation of alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors: dopamine type-1 receptor and protein kinase A dependence.

Authors:  B F Singer; J A Loweth; R L Neve; P Vezina
Journal:  Eur J Neurosci       Date:  2010-03-19       Impact factor: 3.386

Review 5.  Psychostimulant-induced neuroadaptations in nucleus accumbens AMPA receptor transmission.

Authors:  R Christopher Pierce; Marina E Wolf
Journal:  Cold Spring Harb Perspect Med       Date:  2013-02-01       Impact factor: 6.915

6.  Calcium/calmodulin-dependent protein kinase II mediates hippocampal glutamatergic plasticity during benzodiazepine withdrawal.

Authors:  Guofu Shen; Bradley J Van Sickle; Elizabeth I Tietz
Journal:  Neuropsychopharmacology       Date:  2010-05-05       Impact factor: 7.853

7.  Aberrant behavioral sensitization by methamphetamine in junctophilin-deficient mice.

Authors:  Shigeki Moriguchi; Miyuki Nishi; Yuzuru Sasaki; Hiroshi Takeshima; Kohji Fukunaga
Journal:  Mol Neurobiol       Date:  2014-05-22       Impact factor: 5.590

8.  Casein kinase 1 enables nucleus accumbens amphetamine-induced locomotion by regulating AMPA receptor phosphorylation.

Authors:  Dongdong Li; Stacy Herrera; Nancy Bubula; Elena Nikitina; Abraham A Palmer; Dorothy A Hanck; Jessica A Loweth; Paul Vezina
Journal:  J Neurochem       Date:  2011-06-06       Impact factor: 5.372

9.  Threonine 149 phosphorylation enhances ΔFosB transcriptional activity to control psychomotor responses to cocaine.

Authors:  Hannah M Cates; Mackenzie Thibault; Madeline Pfau; Elizabeth Heller; Andrew Eagle; Paula Gajewski; Rosemary Bagot; Christopher Colangelo; Thomas Abbott; Gabby Rudenko; Rachael Neve; Eric J Nestler; Alfred J Robison
Journal:  J Neurosci       Date:  2014-08-20       Impact factor: 6.167

10.  Locomotor conditioning by amphetamine requires cyclin-dependent kinase 5 signaling in the nucleus accumbens.

Authors:  Bryan F Singer; Nichole M Neugebauer; Justin Forneris; Kelli R Rodvelt; Dongdong Li; Nancy Bubula; Paul Vezina
Journal:  Neuropharmacology       Date:  2014-06-02       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.